Edition:
United States

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

33.97USD
23 Feb 2018
Change (% chg)

$0.16 (+0.47%)
Prev Close
$33.81
Open
$33.97
Day's High
$33.97
Day's Low
$33.97
Volume
166
Avg. Vol
13,500
52-wk High
$39.67
52-wk Low
$15.31

Latest Key Developments (Source: Significant Developments)

Albireo Prices $65.0 Mln Public Offering Of Common Stock
Thursday, 25 Jan 2018 08:45am EST 

Jan 25 (Reuters) - Albireo Pharma Inc ::ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.97 MILLION COMMON SHARES PRICED AT $33.00PER SHARE.  Full Article

Albireo Announces Agreement With Healthcare Royalty Partners
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN.ALBIREO PHARMA INC - ‍ALBIREO SUBSIDIARY ELIGIBLE TO RECEIVE UP TO $60 MILLION UNDER AGREEMENT​.ALBIREO PHARMA INC - ‍DECISION ON JAPANESE NEW DRUG APPLICATION FOR ELOBIXIBAT EXPECTED IN FIRST HALF OF 2018​.ALBIREO PHARMA -HCR OBTAINS RIGHT TO RECEIVE ROYALTIES, SALES MILESTONES FOR ELOBIXIBAT IN JAPAN THAT MAY BE PAYABLE BY EA PHARMA, UP TO A THRESHOLD​.ALBIREO PHARMA INC - ‍ELOBIX HAS RETAINED ITS RIGHT TO RECEIVE A MILESTONE PAYMENT FROM EA PHARMA IF ELOBIXIBAT IS APPROVED BY MHLW​.ALBIREO PHARMA INC - ‍ IF SPECIFIED THRESHOLD IS REACHED, ELOBIX WILL AGAIN BECOME ELIGIBLE TO RECEIVE ROYALTIES AND SALES MILESTONES FOR ELOBIXIBAT.  Full Article

Albireo posts Q3 loss per share $0.73‍​
Tuesday, 14 Nov 2017 08:00am EST 

Nov 14 (Reuters) - Albireo Pharma Inc :Albireo reports third quarter 2017 financial results.Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​.Albireo Pharma Inc - ‍revenue totaled $0 for Q3 of 2017 compared with $28,000 for Q3 of 2016​.Albireo Pharma Inc - qtrly loss per share $0.73‍​.Albireo Pharma - ‍expects current cash resources will meet operating requirements till end of 2019, assuming receipt of payment from EA Pharma in 2018​.  Full Article

Albireo Pharma files for mixed shelf of up to $125 million‍​
Friday, 13 Oct 2017 05:43pm EDT 

Oct 13 (Reuters) - Albireo Pharma Inc :Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing‍​ ‍​.  Full Article

EMA paediatric committee agrees to Albireo's A4250 pediatric investigation plan
Tuesday, 26 Sep 2017 08:00am EDT 

Sept 26 (Reuters) - Albireo Pharma Inc ::EMA's paediatric committee agrees to Albireo’s a4250 pediatric investigation plan.Albireo Pharma - ‍completion of pip would provide an additional two years of market exclusivity​.Albireo Pharma - ‍plan to initiate our previously announced phase 3 trial of A4250 by year end​.Albireo Pharma - pdco of EMA agreed to pediatric investigation plan for lead product candidate a4250 in patients with pfic.Albireo Pharma Inc - ‍completion of agreed pip would provide an additional two years of market exclusivity in EU, making a total of 12 years​.  Full Article

Albireo Pharma Q2 loss per share $0.86
Monday, 21 Aug 2017 08:36am EDT 

Aug 21 (Reuters) - Albireo Pharma Inc :Albireo reports second quarter 2017 financial results.Albireo Pharma Inc - qtrly net loss per share diluted $0.86.Q2 earnings per share view $-0.85 -- Thomson Reuters I/B/E/S.  Full Article

Albireo Pharma files non-timely 10-K‍​
Tuesday, 15 Aug 2017 06:15am EDT 

Aug 15 (Reuters) - Albireo Pharma Inc ::Albireo Pharma Inc files non-timely 10-k‍​.Albireo Pharma - unable to file 10-Q quarter ended June 30, 2017 in time due to unexpected delay in preparation of unaudited interim financial statements.Albireo Pharma - delay resulted from ongoing assessment in current period of accounting for correction of understatement of stock compensation expense.  Full Article

Muneer Satter reports 9.77 pct passive stake in Albireo Pharma
Tuesday, 30 May 2017 01:53pm EDT 

May 30 (Reuters) - Albireo Pharma Inc ::Muneer A. Satter reports 9.77 percent passive stake in Albireo Pharma Inc as of May 24, 2017 - SEC filing.  Full Article

Albireo prices $45.1 million public offering of common stock
Wednesday, 24 May 2017 08:39am EDT 

May 24 (Reuters) - Albireo Pharma Inc : :Albireo prices $45.1 million public offering of common stock.Says public offering of 2.20 million common shares priced at $20.50per share.  Full Article

Albireo reports proposed public offering of common stock
Tuesday, 23 May 2017 04:01pm EDT 

May 23 (Reuters) - Albireo Pharma Inc ::Albireo announces proposed public offering of common stock.  Full Article